J Proteome Res:全身地塞米松给药与鼓膜内地塞米松给药对外淋巴蛋白组的影响

2021-08-06 AlexYang MedSci原创

糖皮质激素可通过口服途径全身给药或通过耳内注射局部给药,是突发性感音神经性听力损失的一线治疗选择

糖皮质激素可通过口服途径全身给药或通过耳内注射局部给药,是突发性感音神经性听力损失的一线治疗选择,但对其在内耳中发挥的作用和治疗听力损失的机制却知之甚少。

糖皮质激素受体的免疫抑制作用常常被认为对听力损失具有积极影响,但其他细胞功能也可能存在作用。此外,糖皮质激素的全身给药和局部给药之间的效果差异也没有得到充分阐明。有研究表明,在治疗听力损失方面,IT给药与全身给药一样有效。

近期开发的空心微针能够安全、可靠地对淋巴进行取样来进行蛋白质组分析。

利用空心微针,最近有研究人员调查了耳内(IT)与腹腔内(IP)地塞米松给药对豚鼠淋巴蛋白组的影响。豚鼠在抽吸淋巴前6小时用IT地塞米松(n=6)、IP地塞米松(n=8)或未处理的对照(n=8)进行治疗。通过耳廓后的方法进入圆窗膜(RWM),用空心微针穿透RWM并吸出1μL的淋巴。淋巴样品通过基于液相色谱-质谱技术的无标签定量蛋白质组学进行分析。质谱的原始数据文件已存入国际公共资料库(MassIVE蛋白质组学资料库,网址:https://massive.ucsd.edu/),数据集编号为MSV000086887。在分析的22个淋巴样本中,检测到632个蛋白质,包括淋巴标志物内耳蛋白cochlin。其中,14个蛋白受IP地塞米松调节,3个蛋白受IT地塞米松调节。在IP和IT地塞米松组中,与对照组相比,VGF神经生长因子明显上调。其余变化的蛋白质参与调节神经元、炎症或蛋白质合成。

豚鼠外淋巴蛋白组构成

综上所述,使用空心微针的蛋白质组分析显示,地塞米松的给药途径影响了淋巴周围蛋白质组的变化与IT给药相比,IP途径与更剧烈的蛋白质表达变化有关,包括参与神经保护、炎症途径和蛋白质合成的蛋白质。总之,微针可以介导安全和有效的耳蜗内采样,并为内耳诊断带来希望。

原始出处:

Betsy Szeto , Chris Valentini , Aykut Aksit et al. Impact of Systemic versus Intratympanic Dexamethasone Administration on the Perilymph Proteome. J Proteome Res. Jul 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791787, encodeId=5bca1e9178751, content=<a href='/topic/show?id=a1aa14e64bc' target=_blank style='color:#2F92EE;'>#proteome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14764, encryptionId=a1aa14e64bc, topicName=proteome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 06 19:38:15 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602378, encodeId=7db416023e86d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Aug 08 14:38:15 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005884, encodeId=e70f1005884cd, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Sat Aug 07 21:11:56 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005723, encodeId=08801005e23ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b85561718, createdName=ms5000001003588763, createdTime=Fri Aug 06 23:42:31 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791787, encodeId=5bca1e9178751, content=<a href='/topic/show?id=a1aa14e64bc' target=_blank style='color:#2F92EE;'>#proteome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14764, encryptionId=a1aa14e64bc, topicName=proteome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 06 19:38:15 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602378, encodeId=7db416023e86d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Aug 08 14:38:15 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005884, encodeId=e70f1005884cd, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Sat Aug 07 21:11:56 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005723, encodeId=08801005e23ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b85561718, createdName=ms5000001003588763, createdTime=Fri Aug 06 23:42:31 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-08-08 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791787, encodeId=5bca1e9178751, content=<a href='/topic/show?id=a1aa14e64bc' target=_blank style='color:#2F92EE;'>#proteome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14764, encryptionId=a1aa14e64bc, topicName=proteome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 06 19:38:15 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602378, encodeId=7db416023e86d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Aug 08 14:38:15 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005884, encodeId=e70f1005884cd, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Sat Aug 07 21:11:56 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005723, encodeId=08801005e23ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b85561718, createdName=ms5000001003588763, createdTime=Fri Aug 06 23:42:31 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-08-07 1881ef655dm

    学习啦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1791787, encodeId=5bca1e9178751, content=<a href='/topic/show?id=a1aa14e64bc' target=_blank style='color:#2F92EE;'>#proteome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14764, encryptionId=a1aa14e64bc, topicName=proteome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 06 19:38:15 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602378, encodeId=7db416023e86d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Aug 08 14:38:15 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005884, encodeId=e70f1005884cd, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66942067627, createdName=1881ef655dm, createdTime=Sat Aug 07 21:11:56 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005723, encodeId=08801005e23ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1b85561718, createdName=ms5000001003588763, createdTime=Fri Aug 06 23:42:31 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-08-06 ms5000001003588763

    学习

    0

相关资讯

Eur J Anaesthesiol:术前地塞米松可缓解全膝关节置换术后的疼痛

皮质类固醇可以减轻疼痛,但最佳剂量和安全状况仍不确定。近日,一项前瞻性的随机对照试验评估了两种不同剂量的地塞米松在全膝关节置换术后的疼痛管理及其副作用,研究结果已发表于Eur J Anaesthesi

J Gastroenterol Hepatol:地塞米松对术后胃肠道运动的影响

腹部手术后患者通常会出现一过性的胃肠道运动障碍。近日,一项单中心、双臂、平行、随机对照试验探究了术前单剂量地塞米松是否能促进选择性胃肠道手术后患者的胃肠功能恢复,研究结果已发表于J Gastroent

J Arthroplasty:全髋关节置换术后追加使用地塞米松可提供持续的疼痛缓解和炎症控制

全髋关节置换术(THA)中地塞米松的最佳剂量方案尚不清楚。近日,一项随机试验对比了全髋关节置换术中1剂量、2剂量和3剂量地塞米松的效果,研究结果已发表于J Arthroplasty。

Lancet Oncol:长春新碱联合地塞米松冲击治疗低危ALL患儿1年或就足矣!

对于低危急性淋巴细胞白血病儿童,长春新碱联合地塞米松冲击治疗1年或就足矣

Acta Otolaryngol:地塞米松能保护美尼尔病患者TSCP术后的听力

TSCP在控制难治性美尼尔氏病的眩晕方面显示了其有效性。然而,听力障碍仍然是一个问题,阻碍了手术的应用。近日,研究人员探究了地塞米松对美尼尔病患者在TSCP术后听力的影响,以确定炎症是否参与这一过程,

Reg Anesth Pain Med:选择性全膝关节置换术的局部浸润镇痛中加入地塞米松的效果

全膝关节置换术伴有明显的疼痛,有效的镇痛有利于提高病人的满意度和功能效果。研究表明,地塞米松可能对局部麻醉的作用有促进作用,但这种作用在加入膝关节置换术患者的局部浸润镇痛(LIA)混合物中,还没有得到